Trust linked to ImmunoTech Inc. (AIM) director acquires 2,800 shares

Rhea-AI Filing Summary

ImmunoTech Inc. director David I. Chemerow reported an indirect acquisition of common stock through The David I Chemerow 1992 Trust. On 02/05/2026, the trust acquired 2,800 shares of ImmunoTech common stock at a price of $1.23 per share.

Following this transaction, the trust beneficially owned a total of 3,441 ImmunoTech common shares, all reported as indirectly held on behalf of Chemerow.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHEMEROW DAVID I.

(Last) (First) (Middle)

C/O AIM IMMUNOTECH INC.,

2117 SW HIGHWAY 484

(Street)

OCALA, FL 34473

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		2,800	A	$1.23	3,441	I	The David I Chemerow 1992 Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Chemerow	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ImmunoTech Inc. (AIM) report for David I. Chemerow?

ImmunoTech Inc. reported that director David I. Chemerow had an indirect acquisition of common stock. On 02/05/2026, The David I Chemerow 1992 Trust acquired 2,800 ImmunoTech common shares, with the transaction reported on a Form 4 filing as an acquisition.

How many ImmunoTech Inc. (AIM) shares does the Chemerow trust hold after the Form 4 transaction?

After the reported transaction, The David I Chemerow 1992 Trust beneficially owned 3,441 shares of ImmunoTech common stock. These shares are reported as indirectly owned by director David I. Chemerow in his Form 4, reflecting his indirect beneficial ownership through the trust.

Was the ImmunoTech Inc. (AIM) Form 4 transaction a purchase or sale of shares?

The Form 4 shows an acquisition of ImmunoTech common stock. The transaction code is “A,” indicating 2,800 shares were acquired on 02/05/2026 at a price of $1.23 per share, reported as an indirect holding through The David I Chemerow 1992 Trust.

How is David I. Chemerow related to ImmunoTech Inc. (AIM) in the Form 4 filing?

David I. Chemerow is identified as a director of ImmunoTech Inc. in the Form 4. The filing shows his relationship box checked as “Director,” and it reports his indirect beneficial ownership of common shares through The David I Chemerow 1992 Trust.

Are the ImmunoTech Inc. (AIM) shares held directly or indirectly by David I. Chemerow?

The reported ImmunoTech shares are held indirectly by David I. Chemerow. The Form 4 lists ownership form as “I” for indirect, with the nature of ownership specified as The David I Chemerow 1992 Trust, indicating the shares are held through that trust entity.